Insights

Specialized Focus Aceragen’s dedication to developing therapies for rare and orphan diseases presents a significant opportunity to collaborate with organizations seeking to broaden their portfolio in niche therapeutic areas or to partner on innovative treatments for underserved patient populations.

Financial Movement Despite a limited revenue stream and recent delisting from Nasdaq, Aceragen's recent funding of 35 million dollars highlights their potential to scale research efforts or invest in clinical development, offering avenues for strategic investments or joint ventures.

Community Engagement Aceragen’s emphasis on community awareness and regulatory outreach indicates openness to partnerships with advocacy groups, healthcare providers, and regulatory agencies, opening doors for educational programs and patient-centric initiatives.

Innovation & Technology Utilization of diverse tech stack elements such as WordPress, MySQL, and Amazon ALB demonstrates an adaptive approach to research management and communications, providing opportunities for technological integrations or platform collaborations to enhance clinical or patient engagement tools.

Market Differentiation Focusing on rare and neglected diseases positions Aceragen uniquely in a less saturated market segment, making it an attractive partner for companies or investors aiming to access pioneering treatments with high unmet medical needs.

Similar companies to Aceragen

Aceragen Tech Stack

Aceragen uses 8 technology products and services including cdnjs, RSS, Open Graph, and more. Explore Aceragen's tech stack below.

  • cdnjs
    Content Delivery Network
  • RSS
    Content Management System
  • Open Graph
    Content Management System
  • WordPress
    Content Management System
  • MySQL
    Database
  • jQuery
    Javascript Libraries
  • Amazon ALB
    Load Balancers
  • OpenResty
    Web Servers

Aceragen's Email Address Formats

Aceragen uses at least 1 format(s):
Aceragen Email FormatsExamplePercentage
FLast@aceragen.comJDoe@aceragen.com
50%
FLast@aceragen.comJDoe@aceragen.com
50%

Frequently Asked Questions

Where is Aceragen's headquarters located?

Minus sign iconPlus sign icon
Aceragen's main headquarters is located at 15 tw Alexander Drive Durham, North Carolina 27709 United States. The company has employees across 1 continents, including North America.

What is Aceragen's stock symbol?

Minus sign iconPlus sign icon
Aceragen is a publicly traded company; the company's stock symbol is ACGN.

What is Aceragen's official website and social media links?

Minus sign iconPlus sign icon
Aceragen's official website is aceragen.com and has social profiles on LinkedIn.

What is Aceragen's SIC code NAICS code?

Minus sign iconPlus sign icon
Aceragen's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Aceragen have currently?

Minus sign iconPlus sign icon
As of February 2026, Aceragen has approximately 11 employees across 1 continents, including North America. Key team members include Chief Financial Officer: A. J.. Explore Aceragen's employee directory with LeadIQ.

What industry does Aceragen belong to?

Minus sign iconPlus sign icon
Aceragen operates in the Biotechnology Research industry.

What technology does Aceragen use?

Minus sign iconPlus sign icon
Aceragen's tech stack includes cdnjsRSSOpen GraphWordPressMySQLjQueryAmazon ALBOpenResty.

What is Aceragen's email format?

Minus sign iconPlus sign icon
Aceragen's email format typically follows the pattern of FLast@aceragen.com. Find more Aceragen email formats with LeadIQ.

How much funding has Aceragen raised to date?

Minus sign iconPlus sign icon
As of February 2026, Aceragen has raised $35M in funding. The last funding round occurred on May 03, 2021 for $35M.

When was Aceragen founded?

Minus sign iconPlus sign icon
Aceragen was founded in 2021.

Aceragen

Biotechnology ResearchNorth Carolina, United States11-50 Employees

Aceragen is a rare disease biopharmaceutical company. We address rare, orphan diseases that typically have no available treatment, and strive to develop novel therapies which can have a positive impact on the lives of patients and families. As such, the needs of the patients who suffer from neglected rare diseases drive our mission first-and-foremost. Our goal is to provide rare-disease patients with compelling new therapeutic options that will allow them to lead the fullest lives possible. Such diseases have been frequently overlooked for drug development and remain “orphan” due to the assumption that they have a small individual footprint. We aim to change this outlook, engaging in community awareness, regulatory outreach, and most importantly, delivering novel treatments. By focusing on rare and orphan diseases, we hope to bring a much-needed spotlight to the area by leveraging our collective conviction that these efforts will change the world for the better.

Section iconCompany Overview

Headquarters
15 tw Alexander Drive Durham, North Carolina 27709 United States
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
ACGN
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2021
Employees
11-50

Section iconFunding & Financials

  • $35M

    Aceragen has raised a total of $35M of funding over 1 rounds. Their latest funding round was raised on May 03, 2021 in the amount of $35M.

  • $1M

    Aceragen's revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $35M

    Aceragen has raised a total of $35M of funding over 1 rounds. Their latest funding round was raised on May 03, 2021 in the amount of $35M.

  • $1M

    Aceragen's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.